Persistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC). As proof of principle that the AR remains relevant in CRPC, 2 AR-targeted agents recently approved by the Food and Drug AdministrationVabiraterone and enzalutamideVhave increased overall survival for patients with CRPC in the setting of prior chemotherapy. This review focuses on the AR and 2 direct antagonists, enzalutamide and ARN-509. These nextgeneration AR antagonists offer great promise for patients with advanced disease. Relative to conventional antiandrogens such as bicalutamide, they bind to the receptor with higher affinity, prevent nuclear translocation and DNA binding, and induce apoptosis without agonist activity in preclinical models. The success of these AR-targeted agents in the clinic has changed the landscape of therapy for patients with CRPC, and further therapeutic options building on this platform are currently in development.
I n 1941, Huggins and Hodges 1 demonstrated that prostate cancer is an androgen-dependent disease. Patients with metastatic prostate cancer treated with medical or surgical castration demonstrated significant tumor regressions and palliation of symptoms, but Huggins 2 himself noted in 1966, when he accepted the Nobel Prize in Physiology or Medicine, that endocrine therapy often fails to control the disease. Despite an initial response to androgen deprivation therapy, patients invariably progress to a castration-resistant state in which the cancer will grow despite low levels of serum testosterone (Fig. 1 ). 3 Castration-resistant prostate cancer (CRPC) represents the lethal form of the disease and carries a poor prognosis with, until recently, few treatment options and a median survival of less than 2 years for those with metastatic disease. 4 For decades, patients with CRPC were thought to have ''hormone-refractory'' tumors based on the assumption that clinical progression in the setting of low serum testosterone levels would render additional hormonal manipulations ineffective.
Until recently, options for medical management in these patients beyond palliation have been limited primarily to second-line hormonal agents such as ketoconazole with moderate antitumor effect and cytotoxic agents such as mitoxantrone (which has shown a palliative benefit vs. prednisone alone), 5 docetaxel (which demonstrated an overall survival benefit of 2Y3 months compared with mitoxantrone), 6, 7 and more recently cabazitaxel (which has shown a survival benefit of 2Y3 months in the second-line setting for patients who have already received docetaxel). 8 Fortunately, the outlook for patients with progressive CRPC has changed dramatically over the past few years as drug development has shifted focus from standard chemotherapy to the rational development of targeted approaches based on a fundamental understanding of disease biology. Traditional androgen deprivation therapy does not completely deplete intratumoral androgens or inhibit the expression of androgen receptor (AR) target genes. 9 Overexpression of androgen biosynthetic enzymes also occurs, 10 which in itself can increase intratumoral androgens to a level that is sufficient to drive growth. 9 Abiraterone acetate is a CYP17 inhibitor that decreases intratumoral and extragonadal androgens. Serum androgens are reduced to the 1-2 ng/dl range. 11 Notably, abiraterone acetate was the first hormonal agent targeting an oncogenic change in AR signaling proven to prolong life in men with progressive men with CRPC previously treated with docetaxel (Cougar AA-301: NCT00638690) and the first hormonal agent approved for this indication by the Food and Drug Administration. 12 Enzalutamide (formerly MDV3100) is an AR antagonist and its clinical development is a second important validation of the significance of targeting oncogenic alterations associated with resistance to conventional antiandrogens. Molecular profiling studies identified AR overexpression as a frequent genomic alteration in CRPC. 13 Laboratory studies showed that tumor latency in castrate mice was shorter, and growth was more rapid in LNCaP cells engineered to overexpress AR (LNCaP-AR) relative to those without overexpression. Furthermore, knockdown of the AR with a shRNA inhibited growth. The cells were also stimulated by bicalutamide, suggesting a potential role for AR overexpression in the partial agonist activity of standard antiandrogens. 13 These same cells were then used as a screen to select compounds that optimized growth inhibition without agonist activity, which ultimately led to the identification of enzalutamide for clinical development. 14 In the clinic, anti-tumor activity with enzalutamide was observed at the lowest dose level studied, and the drug progressed rapidly through phase I/II 15 testing into phase III, where the final results of the registration trial showed a 37% reduction in the risk of death for patients treated with enzalutamide relative to placebo. 16 In 2012, enzalutamide was the first next-generation AR antagonist to be FDA approved for the treatment of patients with CRPC who had received prior docetaxel. Together with abiraterone, the results dramatically changed the treatment landscape and established definitively that CRPC are not uniformly ''hormone refractory'' either preor postchemotherapy.
AR FORM AND FUNCTION
The effects of androgens on prostate cancer growth are mediated through the AR signaling pathway. Over the past decade, mounting evidence has shown that the AR remains a critical target in CRPC despite low serum androgen levels. Molecular profiling and laboratory models have confirmed the observation that the AR remains relevant in CRPC by demonstrating diverse mechanisms of continued AR signaling despite castrate levels of serum androgen. Clinically, continued dependence on AR signaling is evident by the observation that rising levels of prostate-specific antigen (PSA), an AR target gene, occur in virtually all patients with progressive disease.
The human AR gene is located on chromosome Xq11-12 and is a steroid hormone receptor member of the larger nuclear receptor family that includes the estrogen, progesterone, and glucocorticoid receptors. The AR is found in benign epithelial cells as well as in all grades and stages of prostate cancer. Functionally, the AR is a 110-kd ligand-activated transcription factor consisting of 917 amino acids that harbors 3 distinct domains of importance. These functional domains include an N-terminal transactivation domain (exon 1), a DNA-binding domain (exons 2 and 3), and a C-terminal ligand-binding domain (LBD, exons 5Y8). Although most steroid hormone receptors rely on activation factor 2 for transcriptional activity, for the AR it is the activation factor 1 region in the N-terminal transactivation domain that drives AR function. 17 In the absence of androgen, the AR associates with heat shock protein 90 complex that acts as a chaperone to prevent AR degradation and to maintain the ligand-binding conformation. Testosterone is a relatively weak ligand, within the prostate it is converted by 5> reductase to the more potent form dihydrotestosterone. 17 When dihydrotestosterone binds to the C-terminal LBD of the AR, there is dissociation from the chaperone complex, resulting in a conformational change and homodimerization of the receptor, translocation into the nucleus, DNA binding, recruitment of cofactors, and ultimately transcription of androgen-dependent genes such as PSA, which is mediated in part by androgen-response elements located on target DNA. 18, 19 There are multiple mechanisms that contribute to continued AR signaling in CRPC that can be exploited to improve upon the current treatment of advanced prostate cancer (Fig. 2 ). These mechanisms include genomic amplification and overexpression of AR, 20 gain-of-function mutations allowing AR to be activated by promiscuous ligands such as steroids or antiandrogens, 21 upregulation of AR enhancer elements, 22 alterations in androgen transport, 23, 24 increased intratumoral androgens and continued synthesis of extragonodal androgen, 25 abnormalities in AR coactivators and coregulators, 26 ligand-independent transactivation of AR by growth factors or cytokines, and AR splice variants that encode for LBD-deficient receptors and are constitutively active but may be dependent upon a full-length receptor for functionality. 27Y29 This review focuses on direct AR antagonism through inhibition of the AR LBD.
FIRST-GENERATION ANTIANDROGENS
The mainstay of treatment for patients with newly diagnosed advanced disease remains suppression of gonadal androgens using a gonadotropin-releasing hormone analog alone or in combination with a conventional antiandrogen such as flutamide, bicalutamide, or nilutamide, which bind to and inhibit the AR. 30, 31 These nonsteroidal antiandrogens are reversible inhibitors that bind to the LBD of AR with low affinity relative to androgens and offer incomplete transcriptional inhibition. 32 Although clinical testing with antiandrogens with a higher affinity for the AR seemed appealing in vitro, the Achilles heel of this class of agents has been the development of AR agonist potential in patients with CRPC. 33 In the setting of AR overexpression, approximately 15% to 30% of patients treated with conventional antiandrogens develop mutations that allow for tumor growth. 21, 34 One proposed mutation is the W741 AR mutation. 35 The agonist potential of drugs such as bicalutamide has been demonstrated in the clinic by the so-called ''antiandrogen withdrawal syndrome,'' in which withdrawal of conventional antiandrogens results in a paradoxical decline in PSA that is indicative of their agonist activity. 36, 37 These limitations of conventional antiandrogens (agonist potential and weak affinity for AR), as well as the discovery that AR gene amplification and overexpression enable prostate cancer to thrive in environments with low levels of circulating androgens, have formed the preclinical basis for developing novel second-generation AR antagonists that directly target the AR LBD and impair nuclear translocation of the receptor complex. 20, 38 
SECOND-GENERATION AR ANTAGONISTS

Enzalutamide
Preclinical Development
Enzalutamide (formerly MDV3100) is the first novel antiandrogen targeting the C-terminal LBD to emerge from a chemical structure-activity relationship program designed to develop more potent antiandrogens. 39 The nonsteroidal hydantoin agonist RU59063 was used as a chemical scaffold to develop a new class of antiandrogens because of its relatively high affinity for AR and its selectivity for AR over other nuclear hormone receptors. The structural units of RU59063 were systematically modified, and the binding affinity, agonism, and antagonism of more than 200 compounds were measured in human prostate cancer cells engineered to overexpress AR. In this way, a new structural class of antiandrogens was developed and the diarylthiohydantoins RD162 and MDV3100 were selected for further study. 40 Preclinical testing of RD162 and MDV3100 in castrationresistant LNCaP/AR human prostate cells demonstrated that they could bind with a 5-to 8-fold greater affinity to AR compared with bicalutamide. Furthermore, treatment with RD162 and MDV3100 did not result in increased AR target gene activity indicative of agonist potential, even in the setting of mutant AR protein expression (W741C), contributing to acquired bicalutamide resistance. 14 Ultimately, MDV3100 was selected to move forward into clinical testing based on its favorable activity and safety profile properties. MDV3100 was shown to impair nuclear translocation, coactivator peptide recruitment, and DNA binding of the AR by inducing a conformational change in the AR distinct from bicalutamide. MDV3100 also caused poly(ADP-ribose) polymerase cleavage indicative of an apoptotic effect, which is not seen with bicalutamide. In LNCaP AR cells in xenograft models, MDV3100 was associated with a statistically significant reduction in tumor volume relative to bicalutamide, which had only minimal effects and no evidence of tumor regressions. 14 
Phase I/II Trial
Based on promising preclinical results, the first-in-man phase I/II trial of the oral next-generation AR antagonist MDV3100 in patients with CRPC was conducted by the Prostate Cancer Clinical Trials Consortium. 15 This trial demonstrated substantial anti-tumor activity for patients treated with MDV3100 both before and after chemotherapy, credentialing the cell-based screen used to identify the compound and other preclinical models. 13, 14 There was evidence of activity based on PSA declines at all dose levels tested, with a plateau in the degree of decline between the 50-and 240-mg dose levels. Twothirds of patients achieved partial remissions or stable disease based on conventional imaging with computed tomography and bone scan.
Experimental biomarkers incorporated into the trial included 18 F-fluoro-5>-dihydrotestosterone (FDHT)Ypositron emission tomography (PET) imaging, which was performed on 22 patients. Analysis of FDHT uptake enables a demonstration of the on-target effects of the drug, and the potential to capture the biological diversity of metastatic sites through visualization of AR binding. 41 18 F-fluoro-5>-dihydrotestosterone-PET imaging showed a reduction in FDHT uptake at 4 weeks after treatment with MDV3100 relative to baseline; this appeared to plateau at a dose of 150 mg despite higher plasma concentrations of MDV3100 at higher doses.
The most common grade 3 or 4 toxicity was dosedependent fatigue (11%). 42 There were 2 witnessed seizures, at 300 and 600 mg, respectively, and 1 possible seizure at 480 mg. Although antiandrogens have been shown to cause seizure activity preclinically through off-target inhibition of F-aminobutyric acid type A currents, 43 it is notable that some patients had potential comorbidities or were receiving medications that could have contributed to seizure activity observed. Ultimately, a dose of 160 mg MDV3100 per day was selected to move forward into phase III study, based on favorable activity of the drug as demonstrated by PSA, conventional imaging, and FDHT responses at 150 mg relative to higher dose levels, which harbored the potential for greater toxicity.
Phase III Trials
The promising phase I/II results with MDV3100 in CRPC set the stage for the 00974311 AFFIRM NCT, a phase III doubleblind study of 1199 men with CRPC following docetaxel-based chemotherapy who were randomized 2:1 to receive MDV3100 or placebo. The trial accrued rapidly between September 2009 and November 2010, involving 156 centers in 15 countries on 5 continents. The study was unblinded by an independent data safety monitoring committee in November 2011, when a planned interim analysis at 520 events showed that treatment with MDV3100 resulted in a 37% reduction in the risk of death as compared with placebo (hazard ratio for death 0.63; 95% confidence interval, 0.53Y0.75; P G 0.001). 16 The AFFIRM trial demonstrated a median overall survival of 18.4 months in the enzalutamide arm (n = 800) versus 13.6 months in the placebo arm (n = 399), and this survival advantage was maintained across all patient subgroups. The proportion of patients showing a 50% or greater decline in PSA posttreatment was 54% in the enzalutamide group versus 2% of the placebo-treated patients (P G 0.001). Enzalutamide was superior in all secondary endpoints including radiographic progression-free survival, time to PSA progression, soft tissue response rate, and patients' responses to the Functional Assessment of Cancer TherapyYProstate quality-of-life questionnaire. The treatment was well tolerated, with common adverse effects including fatigue, diarrhea, and hot flashes. Seizure activity was seen in less than 1% of patients receiving enzalutamide (n = 5). 16 The ongoing phase III PREVAIL trial using enzalutamide versus placebo in men with chemotherapy-naive CRPC (NCT01212991) has completed accrual, with results of the planned interim analysis being eagerly awaited. Because overall survival in a prechemotherapy population can be difficult to demonstrate because of the availability of additional life-prolonging therapies, this study has been designed with a coYprimary endpoint of overall survival and radiographic progression-free survival, similar to the COU-AA-302 study of abiraterone which recently showed a statistically significant improvement in radiographic progressive free survival. 44 
ARN-509
Preclinical Development ARN-509 is a next-generation antiandrogen that also directly binds to the LBD of AR with high affinity, inhibiting its nuclear import and DNA-binding capacity. Notably, ARN-509 has several preclinical properties that distinguish it from MDV3100 and support a higher therapeutic index: (1) ARN-509 achieves greater anti-tumor activity at a lower dose and exposure than MDV3100; (2) steady-state levels of ARN-509 are 2-to 4-fold lower than MDV3100 at equivalent doses, whereas intratumoral levels are equivalent, indicative of a higher tumor/plasma ratio for ARN-509; and (3) central nervous system levels of ARN-509 are 4-fold lower than MDV3100, suggesting a reduced risk of seizure activity. 45 
Phase I/II Trial
Ongoing phase I/II analysis of ARN-509 in patients with CRPC has demonstrated that the drug is safe and well tolerated, with linear pharmacokinetics consistent with preclinical models. 46 There has been evidence of anti-tumor activity based on PSA and imaging. To ensure the most accurate dosing of ARN-509, the phase I trial used FDHT-PET imaging to confirm the recommended phase II dose of 240 mg daily. There was no appreciable difference in uptake at higher doses, suggesting that the maximal efficacy of the drug might be reached before reaching the maximum tolerated dose.
The phase II study of ARN-509 is ongoing and was designed to evaluate the activity of ARN-509 in 3 distinct patient populations of men with CRPC: (1) patients with nonmetastatic CRPC who are treatment-naive (without prior chemotherapy or second-generation antiandrogen exposure), (2) patients with metastatic CRPC who are treatment-naive, and (3) patients with metastatic CRPC previously treated with abiraterone acetate who are chemotherapy-naive. Preliminary results for the nonmetastatic and metastatic populations were presented in 2012 in 2 separate abstracts at the European Society of Medical Oncology Congress. 47, 48 The primary endpoint was the rate of a 50% or greater decline in PSA at 12 weeks according to the Prostate Cancer Working Group 2 criteria 49 in each of the 3 treatment groups. Secondary endpoints included safety, time to PSA progression, and objective response rates. All patients received prior treatment with a luteinizing hormoneYreleasing hormone analog, with or without a first-generation antiandrogen. The most common treatment-related adverse events were fatigue and gastrointestinal events. At 12 weeks, the proportions of patients in each of the 3 subgroups demonstrating 50% decline in PSA or greater from baseline were 91% (nonmetastatic, treatment-naive), 88% (metastatic, treatment-naive), and 29% (metastatic, postYabiraterone treatment). Final analysis is ongoing, with evidence of promising preliminary activity in patients with high-risk nonmetastatic and metastatic, chemotherapy-naive CRPC both before and after treatment with abiraterone.
FUTURE DIRECTIONS
Given the fulfilled promise of AR-targeted agents for patients with CRPC, a number of new AR-directed therapies capitalizing on this success are in early clinical development (Table 1) . ODM-201 is a second-generation antiandrogen similar in mechanism to enzalutamide and ARN-509, but that does not cross the blood-brain barrier in preclinical models. 50 This has significant implications for next-generation AR antagonists, since seizure activity, albeit at a low frequency, is a concern for antiandrogens as a possible class effect at higher exposures. 43 Another small molecule inhibitor of AR that binds to the AR LBD is AZD-3514. In addition to inhibition of AR translocation into the nucleus and subsequent transcription of AR-regulated genes, AZD-3514 demonstrates a reduction in AR protein levels in vitro, which is a mechanism distinct from that of bicalutamide and other second-generation antiandrogens. 51 Additional potential AR antagonists in clinical development include EZN-4176, a novel, locked, nucleic acidbased antisense oligonucleotide against AR that has demonstrated selective and specific down-modulation of AR mRNA and protein in preclinical models, 52 and TOK-001, a selective CYP17 lyase inhibitor that has been shown to downregulate and antagonize AR in xenograft models. 53 Unfortunately, although AR antagonists have provided benefit to many, not all patients respond to therapy, and among those who do, the durability of response is often limited. In the clinic, we have observed the following patterns of response to AR-targeted therapy with enzalutamide: dramatic declines in PSA with durable radiographic control, an intermediate response characterized by a slowly rising PSA, and a proportion of patients who do not respond (Fig. 3) . Recognizing that PSA is not a surrogate for survival and that patients with a slowly rising PSA might still derive benefit from continuing treatment, the Prostate Cancer Working Group 2 guidelines were incorporated into the phase III trials of enzalutamide and abiraterone to ensure that patients could remain on study treatment until radiographic (as opposed to PSA) progression. 49 These varied patterns of response to AR-targeted treatment will require an increased understanding of the mechanisms contributing to sensitivity and resistance to advance the field and provide maximal benefit to patients with CRPC who will otherwise succumb to their disease.
In the laboratory, resistance to enzalutamide has been recapitulated in xenograft models, suggesting both non-AR mechanisms and AR splice forms that lack the LBD, as mediators of progression. 54 Approximately 25 variants of posttranscriptional AR splice variants have been identified, the most significant of which appear to be those in which the AR ligandYbinding domain (LBD) is lost, resulting in ligandindependent constitutive AR activation. 55 In a subset of CRPC xenograft models treated with enzalutamide, there is an adaptive shift away from the full-length AR toward the AR splice variant, suggesting castration as an important mechanism contributing to drug resistance in prostate cancer progression. 56 Because first-and second-generation antiandrogens bind to the C-terminal LBD, newer methods of targeting the AR include targeting the regulatory N-terminal domain, which is essential for transcription in the presence or absence of ligand. 57 EPI-001 is a novel, small molecule peptide that binds to the N-terminus and disrupts transcription and protein-protein interactions. EPI-001 does not reduce levels of AR protein, but because it is not dependent on ligand, it may have activity in the setting of AR splice variants. 58 In LNCaP xenograft models, treatment with EPI-001 has caused decreased AR gene expression and inhibited tumor growth, 59 suggesting that this class of agents might have activity against AR splice variants.
Another avenue of exploration focusing on resistance to AR-targeted therapy is the inhibition of multiple signaling pathways such as the PI3K (phosphatidylinositol 3-OH kinase) pathway through reciprocal feedback inhibition. Using xenograft models and genetically engineered mouse models, it has been shown that prostate tumors with loss of the tumor suppressor Pten are resistant to next-generation antiandrogens. 60, 61 Notably, this resistance can be overcome by combined AR and PI3K/mTOR (mammalian target of rapamycin) pathway inhibition. The mechanism of synergy is through reciprocal negative feedback: inhibition of either single pathway activates the other, thereby protecting the tumor cells from death. The most immediate implication of these data is that combinatorial AR + PI3K/mTOR inhibitor therapy could be highly effective in CRPC. The concept of combining hormonal therapy with PI3K/mTOR pathway inhibition has recently been validated in breast cancer in the BOLERO-2 trial. 62 This phase III study demonstrated superiority of an mTOR inhibitor (everolimus) combined with an aromatase inhibitor (exemestane) in extending progression-free survival of women with metastatic breast cancer when compared with exemestane alone and is readily applicable to the population of men with CRPC.
CONCLUSIONS
Agents targeting specific molecular alterations in human prostate tumors have changed the landscape of treatment for prostate cancer by validating the importance of the AR across all clinical states in the management of the disease. Nextgeneration AR antagonists such as enzalutamide and ARN-509, both of which impair nuclear translocation of the AR and subsequent transcription of AR target genes, represent a giant leap forward in understanding the underlying molecular mechanisms of disease progression and have been applied in a meaningful way to benefit patients in the clinic. Additional exploration of treatments building on the increasing understanding of the AR signaling pathway is underway and offers great hope for patients with CRPC who would otherwise succumb to their disease.
